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Abstract
Background: Dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylates (1,4-DHP) have now been recognized as
vital drugs. Some of these derivatives such as amlodipine, felodipine, isradipine, etc. have been commercialized. In
view of wide range of biological properties associated with 1,4-DHP and owing to the biological importance of the
oxidation step of 1,4-DHP, we carried out the synthesis and antimicrobial evaluation of new diethyl 1,4-dihydro-2,6-
dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-
4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g).
Results: Synthesis of a series of new diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-
dicarboxylates (2a-g) has been accomplished by multicomponent cyclocondensation reaction of ethyl
acetoacetate, 3-aryl-1-phenyl pyrazole-4-carboxaldehyde (1a-g) and ammonium acetate. The dihydropyridines 2a-g
were smoothly converted to new diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-
g) using HTIB ([Hydroxy (tosyloxy)iodo]benzene, Koser’s reagent) as the oxidizing agent. The antimicrobial studies
of the title compounds, 2a-g &3a-g, are also described.
Graphical abstract
Synthesis of a series of new diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-
dicarboxylates (2a-g), their aromatization using HTIB ([Hydroxy(tosyloxy)iodo]benzene, Koser’s reagent) to afford
new diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g), and antimicrobial studies
of 2a-g and 3a-g are reported.
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Background
Dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxy-
lates (1,4-DHP; Figure 1) have now been recognized as
vital drugs. Some of these derivatives, such as amlodi-
pine, felodipine, isradipine, etc. have been
commercialized, and it has been proven that their thera-
peutic success is related to their efficacy to bind to cal-
cium channels and consequently to decrease the passage
of the transmembrane calcium current [1-3]. Further,
cerebrocrast, a dihydropyridine derivative, has been
introduced as a neuroprotective agent [4]. Together
with calcium channel blocker and neuroprotective activ-
ity, a number of dihydropyridine derivatives have been
found as vasodilators, antihypertensive, bronchodilators,
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provided the original work is properly cited.antiatherosclerotic, hepatoprotective, antitumour, anti-
mutagenic, geroprotective, antidiabetic and antiplatelet
aggregation agents [5-9]. In a recent article, 4-[5-chloro-
3-methyl-1-phenyl-1H-pyrazol-4-yl]-dihydropyridines
have been shown to possess significant antimicrobial
activity [10].
In addition to above, aromatization of 1,4-DHP has
also attracted considerable attention in recent years as
Böcker has demonstrated that metabolism of the above
drugs involves a cytochrome P-450 catalysed oxidation
in the liver [11].
In view of wide range of biological properties asso-
ciated with 1,4-DHP and the biological importance of
the oxidation step of 1,4-DHP, we carried out the synth-
esis and antimicrobial evaluation of new diethyl 1,4-
dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyr-
idine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-
4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxy-
lates (3a-g).
Results and discussion
Chemistry
The synthetic scheme used for the synthesis of diethyl
1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)
pyridine-3,5-dicarboxylates (2a-g) is outlined in Scheme
1. Synthesis of the title compounds 2a-g was accom-
plished by multicomponent cyclocondensation reaction
of ethyl acetoacetate, 3-aryl-1-phenyl-pyrazole-carboxal-
dehyde (1a-g) and ammonium acetate in ethanol. The
purity of the compounds was checked by TLC and ele-
mental analysis. Spectral data (IR,
1H NMR (see addi-
tional files 1, 2, 3, 4 and 5, mass) of the newly
synthesized compounds 2a-g were in full agreement
with their proposed structures. The IR spectra of com-
pounds 2a-g exhibited characteristic peak at approxi-
mately 1697 cm
-1 because of the presence of ester group
(-COOEt), and peak due to -N-H stretch appeared in
the region 3300-3317 cm
-1.I n
1HN M Ro fc o m p o u n d s
2a-g, the protons of C4-H and -NH of the dihydropyri-
dine ring resonate between δ 5 and 6 ppm.
Hypervalent iodine (III) and iodine (V) reagents have
been used as green-oxidants for a variety of substrates
[12-17]. Amongst the various reagents used, HTIB has
been reported to serve as a mild, fast and efficient oxi-
dant for the aromatization of Hantzsch 1,4-dihydropyri-
dines to pyridines [18].
Thus, diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-
phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)
were further oxidized by treating with HTIB (Koser’s
reagent) in dichloromethane (CH2Cl2) at room tempera-
ture to afford new diethyl 2,6-dimethyl-4-(3-aryl-1-phe-
nyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (3a-g)i n
good-to-excellent yields (Scheme 1). All the compounds
3a-g were unambiguously characterized on the basis of
their spectral (IR,
1H NMR (see additional files 6, 7, 8,
9, 10, 11 and 12) and mass) and elemental data.
A plausible mechanism for the oxidation of dihydro-
pyridines 2 to 3 is outlined in Scheme 2. The probable
mechanism might involve the attack by N-H on PhI
(OH)OTs, leading to the formation of intermediate 4.
The intermediate 4 finally loses a molecule of iodoben-
zene (PhI) to give 3.
Figure 1 1,4-DHP.
Scheme 1 Synthesis of 1,4-DHP (2) and aromatization of 2 to 3
using HTIB.
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All the synthesized compounds, 2a-g and 3a-g,w e r e
evaluated in vitro for their antibacterial activity against
two gram-positive bacterial strains, Staphylococcus aur-
eus &Bacillus subtilis and two gram-negative bacteria,
namely, Escherichia coli and Pseudomonas aeruginosa
and their activities were compared with a well-known
commercial antibiotic, ciprofloxacin. In addition, the
synthesized compounds were also evaluated for their
antifungal activity against Aspergillus niger &Aspergillus
flavus and their antifungal potential was compared to
reference drug, fluconazole. Compounds possessed vari-
able antibacterial activities against Gram-positive bac-
teria, S. aureus, B. subtilis. However, the compounds in
this series were not effective against any Gram-negative
bacteria, neither against E. coli nor against P. aeruginosa.
Results of antibacterial evaluation are summarized in
Table 1.
Compounds 2a-g and 3a-g showed zones of inhibition
ranging between 14 and 20 mm. On the basis of the
zones of inhibition produced against the test bacteria,
compounds 2b and 3a were found to be most effective
against S. aureus, showing the maximum zones of inhi-
bition at 18 and 20 mm, respectively, and compounds
3a, 3e and 3g were found to be most effective against B.
subtilis. The remaining compounds showed fair activity
against gram-positive bacterial strains (Table 1). In the
whole series, the MIC (minimum inhibitoty concentra-
tion) values of various tested chemical compounds ran-
ged between 64 and 256 μg/mL against gram-positive
bacteria. Compounds 2b and 3a displayed good antibac-
terial activity with the lowest MIC value, 64 μg/ml
against S. aureus. Three compounds, 3a, 3e and 3g pos-
sessed antibacterial activity with MIC value of 64 μg/mL
against B. subtilis (Table 2).
Amongst the synthesized compounds, six compounds
2a, 2d,2 g,3 a, 3c and 3d showed more than 50% myce-
lial growth inhibition against A. niger whereas com-
pounds, 2a, 2e, 2f, 3a, 3d and 3f were found to be
active against A. flavus (Table 3).
From the overall result it is evident that compound 3a
could be identified as the most biologically active mem-
ber within this study with good antifungal and antibac-
terial profile.
Conclusions
A series of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-
phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g)
and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)
pyridine-3,5-dicarboxylates (3a-g)h a sb e e ns y n t h e s i z e d
with the hope of discovering new structure leads. Com-
pounds 2b and 3a w e r ef o u n dt ob em o s te f f e c t i v e
against S. aureus showing the maximum zones of inhibi-
tion of 18 and 20 mm, respectively, and compounds 3a,
3e and 3g were found to be most effective against B.
subtilis. Moreover, six compounds 2a, 2d, 2g, 3a, 3c
and 3d showed more than 50% mycelial growth inhibi-
tion against A. niger whereas compounds, 2a, 2e, 2f, 3a,
3d and 3f were found to be active against A. flavus;
however, no compound was found superior over the
reference drug.
Scheme 2 Proposed mechanism for the oxidation of 2 to 3.
Table 1 Antibacterial activity of chemical compounds
through agar well diffusion method
Compound Diameter of growth of inhibition zone (mm)
a
S. aureus Bacillus Subtilis E. coli P. aeruginosa
2a 15.6 16.3 - -
2b 18.6 15.6 - -
2c 16.3 15.6 - -
2d 17.6 16.3 - -
2e 16 15.3 - -
2f 15.6 14 - -
2g 15.3 16.6 - -
3a 20 19.3 - -
3b 15 15.6 - -
3c 15.3 16.6 - -
3d 16.6 14.6 - -
3e 16.6 18.3 - -
3f 15.3 16.6 - -
3g 16.3 18.6 - -
Ciprofloxacin 27.6 26.3 25.0 25.3
-, No activity
aValues, including diameter of the well (8 mm), are means of three replicates
Table 2 MIC (in μg/mL) of compounds obtained using
macrodilution method
Compound S.
aureus
Bacillus
Subtilis
Compound S.
aureus
Bacillus
Subtilis
2a 128 128 3a 64 64
2b 64 128 3b 128 128
2c 128 128 3c 128 128
2d 128 128 3d 128 256
2e 128 128 3e 128 64
2f 128 256 3f 128 128
2g 128 128 3g 128 64
Ciprofloxacin 5 5
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biologically active member within this study with an
interesting antibacterial and antifungal profile.
Experimental
Chemical synthesis
Melting points were taken in open capillaries and are
uncorrected. IR spectra were recorded on Perkin-Elmer
IR spectrophotometer. The
1H NMR spectra were
recorded on Brucker 300 MHz instrument. The chemi-
cal shifts are expressed in ppm units downfield from an
internal TMS standard. 3-Aryl-1-phenylpyrazole-4-car-
boxaldehydes (1a-h), needed for the present study, were
synthesized by Vilsmeier-Haack reaction according to
the literature procedure [19].
Synthesis of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-
phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)
General procedure: A mixture of appropriate 3-aryl-1-
phenylpyrazole-4-carboxaldehyde (1, 10 mmol), ethyl
acetoacetate (20 mmol) and ammonium acetate (22
mmol) in ethanol was allowed to reflux on water bath
for 25-30 min. After completion of the reaction, the
reaction mixture was cooled to room temperature to
give pure diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-
phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g).
Characterization data of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-
aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)
2a: M.p.: 124°C; yield: 74%; IR (νmax,c m
-1, KBr): 3323
(NH stretch), 1690 (-COOEt), 1207;
1H NMR (CDCl3, δ,
ppm): 1.069-1.115 (t, 6H), 2.237 (s, 6H), 3.744-4.068 (m,
4 H), 5.318 (s, 1 H), 5.544 (s, 1 H), 7.221-7.424 (m, 4
H), 7.806 (s, 1 H), 7.681-7.868 (m, 6 H); mass: m/z
472.30 (M
+ + 1, 100%).
Anal. Calcd for C28H29N3O4: C 71.33, H 6.15, N 8.91;
found: C 71.34, H 6.18, N 8.94; C 71.33, H 6.15, N 8.91.
2b: M.p.: 189°C; yield: 70%; IR (νmax,c m
-1, KBr): 3325
(NH stretch), 1697 (-OOEt), 1643, 1211;
1HNMR
(CDCl3, δ, ppm): 1.032-1.087 (t, 6 H), 2.225 (s, 6 H),
2.401 (s, 3 H), 3.730-4.095 (m, 4 H), 5.306 (s, 1 H),
5.722 (bs, 1 H), 7.205-7.282 (m, 3 H), 7.381-7.450 (m, 2
H), 7.664-7.692 (m, 2 H), 7.733 (s, 1 H), 7.742-7.769 (d,
2H ,J = 8.1 Hz); mass: m/z 486.20 (M
+ + 1, 100%).
Anal. Calcd for C29H31N3O4: C 71.75, H 6.39, N 8.66;
found: C 71.71, H 6.42, N 8.66.
2c: M.p.: 139°C; yield: 78%; IR (νmax,c m
-1,K B r ) :3 3 1 7
(NH stretch), 1697 (-COOEt), 1643, 1211;
1HN M R
(CDCl3, δ, ppm): 1.079-1.127 (t, 6 H), 2.250 (s, 6 H),
3.866 (s, 3 H), 3.801-4.102 (m, 4 H), 5.288 (s, 1 H),
5.561 (s, 1 H), 6.962-6.991 (d, 2 H, J = 8.7 Hz), 7.209-
7.440 (m, 3 H), 7.670-7.697 (d, 2 H, J = 8.7 Hz) 7.742 (s,
1 H), 7.785-7.814 (d, 2 H, J =8 . 7H z ) ;m a s s :m/z 502.32
(M
+ + 1, 100%).
Anal. Calcd for C29H31N3O5: C 69.46, H 6.19, N 8.38;
found: C 69.42, H 6.24, N 8.37.
2d: M.p.: 175°C; yield: 72%; IR (νmax,c m
-1, KBr): 3333
(NH stretch), 1697 (-COOEt), 1643, 1211;
1HN M R
(CDCl3, δ, ppm): 0.940-0.975 (t, 6 H), 2.521 (s, 6 H),
4.102-4.132 (m, 4 H), 5.175 (s, 1 H), 5.562 (s, 1 H),
6.962-6.991 (d, 2 H, J = 8.7 Hz), 7.281-7.513 (m, 5 H),
7.734 (d, 2 H, J = 7.5 Hz), 7.922 (s, 1 H); mass: m/z
490.26 (M
+ + 1, 100%)
Anal. Calcd for C28H28N3O4F: C 68.71, H 5.73, N
8.58; found: C 68.72, H 5.75, N 8.56.
2e: M.p.: 185°C; Yield: 76%; IR (νmax,c m
-1, KBr): 3317
(NH stretch), 1697 (-COOEt), 1636, 1211;
1HN M R
(CDCl3, δ, ppm): 1.072-1.119 (t, 6 H), 2.280 (s, 6 H),
3.790-4.080 (m, 4 H), 5.285 (s, 1 H), 5.551 (s, 1 H),
7.235-7.454 (m, 5 H), 7.668-7.694 (d, 2 H) 7.814 (s, 1
H), 7.863-7.891 (d, 2 H, J = 8.4 Hz); mass: m/z 506.26,
508.24.
Anal. Calcd for C28H28N3O4Cl: C 66.47, H 5.54, N
8.31; found: C 66.47, H 5.55, N 8.31.
2f:M . p . :1 7 4 ° C ;y i e l d :7 2 % ;I R( νmax,c m
-1, KBr): 3564
(NH stretch), 1728 (-COOEt), 1242;
1H NMR (CDCl3, δ,
ppm): 1.072-1.119 (t, 6 H), 2.275 (s, 6 H), 3.764-4.104
(m, 4 H), 5.284 (s, 1 H), 5.581 (s, 1 H), 7.234-7.452 (m,
3 H), 7.561-7.588 (d, 2 H, J = 7.8 Hz), 7.665-7.691 (d, 2
H, J = 7.8 Hz) 7.753 (s, 1 H), 7.806-7.834 (d, 2 H, J =
8.4 Hz); mass: m/z 550.31, 552.31.
Anal. Calcd for C28H28N3O4Br: C 61.20, H 5.10, N
7.65; found: C 61.09, H 5.14, N 7.64.
2g: M.p.: 198°C; yield: 70%; IR (νmax,c m
-1, KBr): 3302
(NH stretch), 1697 (-COOEt), 1636, 1211;
1HN M R
(CDCl3, δ, ppm): 1.026-1.071 (t, 6 H), 2.325 (s, 6 H),
3.775-4.047 (m, 4 H), 5.335 (s, 1 H), 5.766 (s, 1 H),
7.282-7.473 (m, 4 H), 7.684-7.709 (d, 2 H, J =7 . 5H z ) ,
7.801 (s, 1 H), 8.254-8.344 (m, 3 H); mass: m/z 517.29
(M
+ + 1, 100%).
Anal. Calcd for C28H28N4O6: C 65.11, H 5.42, N 10.85;
found: C 65.13, H 5.47, N 10.83.
Synthesis of diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-
pyrazolyl)pyridine-3,5-dicarboxylates (3a-g)
General procedure: To a solution of appropriate 1,4-
DHP (2, 10 mmol) in dichloromethane, was added
Table 3 Antifungal activity of chemical compounds
through poisoned food method (mycelial growth
inhibition) (%)
Compound A. niger A. flavus Compound A. niger A. flavus
2a 51.1 58.8 3a 52.5 51.1
2b 50 44.4 3b 48.8 45.5
2c 48.8 50 3c 51.1 50
2d 52.5 48.8 3d 55.5 52.5
2e 45.5 51.1 3e 45.5 44.4
2f 47.7 52.5 3f 50 51.1
2g 51.1 48.8 3g 48.8 44.4
Fluconazole 81.1 77.7
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temperature. The progress of the reaction was moni-
tored by TLC. Reaction was completed in 4-5 min.
After the completion of reaction, the reaction mixture
was washed with aqueous NaHCO3 solution. Organic
phase was then separated, dried and concentrated on
water bath. Crude product, thus obtained, was purified
by silica gel column chromatography using Pet ether/
EtOAc (20:1) as eluent to afford pure diethyl 2,6-
dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-
dicarboxylates (3a-g).
Characterization data of dimethyl 2,6-dimethyl-4-
pyrazolylpyridine-3,5-dicarb oxylates (3a-g)
3a: M.p.: 111°C; yield: 68%; IR (νmax,c m
-1, KBr): 1736,
1233;
1HN M R( C D C l 3, δ, ppm): 0.911-0.997 (t, 6 H),
2.613 (s, 6 H), 3.910-4.07 (m, 4 H), 7.110-7.313 (m, 4
H), 7.817 (s, 1 H), 7.581-7.690 (m, 6 H); mass: m/z
470.20 (M
+ + 1, 100%).
Anal. Calcd for C28H27N3O4: C 71.64, H 5.76, N 8.95;
found: C 71.63, H 5.79, N 8.93.
3b: M.p.: 105°C; yield: 69%; IR (νmax,c m
-1, KBr): 1720,
1234;
1HN M R( C D C l 3, δ, ppm): 0.913-0.960 (t, 6 H),
2.611 (s, 6 H), 2.468 (s, 3H), 3.923-4.072 (q, 4 H), 6.839-
6.868 (d, 2H, J=8.7 Hz), 7.280-7.501 (m, 5 H), 7.732-
7.759 (d, 2 H, J = 8.7 Hz), 7.905 (s, 1 H); mass: m/z
484.40 (M
+ + 1, 100%).
Anal. Calcd for C29H29N3O4: C 72.05, H 6.00, N 8.70;
found: C 72.06, H 6.05, N 8.70.
3c: M.p.: 136°C; Yield- 72%; IR (νmax,c m
-1, KBr): 1740,
1034;
1HN M R( C D C l 3, δ, ppm): 0.913-0.998 (t, 6 H),
2.612 (s, 6 H), 3.808 (s, 3 H), 3.924-4.08 (q, 4 H), 6.835-
6.864 (d, 2 H, J = 8.7 Hz), 7.311-7.501 (m, 5 H), 7.732-
7.759 (d, 2 H, J = 8.7 Hz), 7.905 (s, 1 H); mass: m/z
500.29 (M
+ + 1, 100%).
Anal. Calcd for C29H29N3O5: C 69.73, H 5.81, N 8.41;
found: C 69.71, H 5.83, N 8.40.
3d: M.p.: 121°C; yield: 70%; IR (νmax,c m
-1, KBr): 1728,
1236, 1037;
1HN M R( C D C l 3, δ, ppm): 0.924-0.971 (t, 6
H), 2.615 (s, 6 H), 3.905-4.105 (q, 4 H), 6.987-7.044 (m,
2 H), 7.280-7.365 (m, 1 H), 7.469-7.622 (m, 4 H), 7.733-
7.759 (d, 2 H, J = 7.8 Hz), 7.923 (s, 1 H); mass: m/z
488.36 (M
+ + 1, 100%).
Anal. Calcd for C28H26N3O4F: C 68.99, H 5.38, N
8.62; found: C 68.95, H 5.37, N 8.63.
3e: M.p.: 101-102°C, lit [20] M.p.: 101-102°C; Yield:
65%.
3f: M.p.: 115°C; yield: 70%; IR (νmax,c m
-1, KBr): 1734,
1030;
1HN M R( C D C l 3, δ, ppm): 0.940-0.962 (t, 6 H),
2.617 (s, 6 H), 3.957-4.039 (q, 4 H), 7.200-7.495 (m, 7
H), 7.732-7.756 (d, 2 H, J = 7.2 Hz), 7.921 (s, 1 H);
mass: m/z 548.20, 550.20.
Anal. Calcd for C28H26N3O4Br: C 61.42, H 4.75, N
7.68; found: C 61.31, H 4.79, N 7.69.
3g: M.p.: 172°C; yield: 68%; IR (νmax,c m
-1, KBr): 1728,
1234, 1034;
1HN M R( C D C l 3, δ, ppm): 0.895-0.941 (t, 6
H), 2.632 (s, 6 H), 3.923-4.039 (m, 4 H), 7.279-7.410 (m,
3 H), 7.499-7.769 (m, 4 H), 7.960 (s, 1 H), 8.178-8.207
(d, 2 H, J = 7.5 Hz); mass: m/z 515.26 (M
+ + 1, 100%).
Anal. Calcd for C28H26N4O6: C 64.37, H 4.98, N 10.73;
found: C 65.34, H 5.08, N 10.87.
Pharmacology
Test microorganisms
Total six microbial strains were selected on the basis of
their clinical importance in causing diseases in humans.
Two Gram-positive bacteria (S. aureus MTCC 96 and B.
subtilis MTCC 121); two Gram-negative bacteria (E. coli
MTCC 1652 and P. aeruginosa MTCC 741) and two
fungi (A. niger and A. flavus) the ear pathogens isolated
from the patients of Kurukshetra [21], were used in the
present study for the evaluation of antimicrobial activ-
ities of the chemical compounds. All the cultures were
procured from Microbial Type Culture Collection
(MTCC), IMTECH, Chandigarh. The bacteria and fungi
were subcultured on Nutrient agar and Sabouraud’s dex-
trose agar (SDA), respectively, and incubated aerobically
at 37°C.
In vitro antibacterial activity
The antibacterial activities of compounds, 2a-g and 3a-
g, were evaluated by the agar well diffusion method. All
the cultures were adjusted to 0.5 McFarland standard,
which is visually comparable to a microbial suspension
of approximately 1.5 × 10
8 c f u / m L .2 0m Lo fM u e l l e r
Hinton agar medium was poured into each Petri plate,
and the agar plates were swabbed with 100 μLi n o c u l a
of each test bacterium and kept for 15 min for adsorp-
tion. Using sterile cork borer of 8-mm diameter, wells
were bored into the seeded agar plates, and these were
then loaded with a 100 μL volume with concentration of
2.0 mg/mL of each compound reconstituted in the
dimethylsulphoxide (DMSO). All the plates were incu-
bated at 37°C for 24 h. Antibacterial activity of each
compound was evaluated by measuring the zone of
growth inhibition against the test organisms with zone
reader (Hi Antibiotic zone scale). DMSO was used as a
negative control whereas ciprofloxacin was used as a
positive control. This procedure was performed in three
replicate plates for each organism [22,23].
Determination of minimum inhibitory concentration
Minimum inhibitory concentration (MIC) is the lowest
concentration of an antimicrobial compound that will
inhibit the visible growth of a microorganism after over-
night incubation. MIC of the compounds against bacter-
ial strains was tested through a macrodilution tube
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method, various test concentrations of chemically
synthesized compounds were made from 256 to 1 μg/
mL in sterile tubes, 1-10. 100 μL sterile Mueller Hinton
Broth was poured in each sterile tube, and followed by
addition of 200 μL test compound in tube 1. Twofold
serial dilutions were carried out from tubes 1 to 10, and
excess broth (100 μL )w a sd i s c a r d e df r o mt h et u b e1 0 .
To each tube, 100 μL of standard inoculum (1.5 × 10
8
cfu/mL) was added. Ciprofloxacin was used as control.
Turbidity was observed after incubating the inoculated
tubes at 37°C for 24 h.
In vitro antifungal activity
The antifungal activity of the synthesized chemical com-
pounds was evaluated by poison food technique. The
m o u l d sw e r eg r o w no nS D Aa t2 5 ° Cf o r7d a y sa n d
used as inocula. 15 mL of molten SDA (45°C) was poi-
soned by the addition of 100 μL volume of each com-
pound having concentration of 4.0 mg/mL,
reconstituted in the DMSO, poured into a sterile Petri
plate and allowed to solidify at room temperature. The
solidified poisoned agar plates were inoculated at the
centre with fungal plugs (8-mm diameter), obtained
from the actively growing colony and incubated at 25°C
for 7 days. DMSO was used as the negative control
whereas fluconazole was used as the positive control.
The experiments were performed in triplicates. Dia-
meter of the fungal colonies was measured and
expressed as percent mycelial inhibition determined by
applying the following formula [25]:
Inhibition of mycelial growth % = (dc − dt)/dc × 100
where dc is the average diameter of fungal colony in
negative control plates, and dt the average diameter of
fungal colony in experimental plates.
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